

Opioid analgesic stewardship: 3b - Proportion of patients who were newly prescribed opioid analgesics who were co-prescribed central nervous system depressant medicines while in hospital

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Opioid analgesic stewardship: 3b - Proportion of patients who were newly prescribed opioid analgesics who were co-prescribed central nervous system depressant medicines while in hospital

Identifying and definitional attributes

Metadata item type:	Indicator
Indicator type:	Indicator
Short name:	3b - Proportion of patients who were newly prescribed opioid analgesics who were co-prescribed central nervous system depressant medicines while in hospital
METEOR identifier:	755552
Registration status:	Australian Commission on Safety and Quality in Health Care, Standard 27/04/2022
Description:	The proportion of patients who were newly prescribed opioid analgesics who were co-prescribed central nervous system (CNS) depressant medicines while in hospital.
Rationale:	Co-administration of opioid analgesics and CNS depressants (such as benzodiazepines and other sedative hypnotics, barbiturates, gabapentinoids, alcohol and recreational drugs) is a modifiable, avoidable risk factor for sedation and respiratory depression.
Indicator set:	Clinical care standard indicators: Opioid Analgesic Stewardship in Acute Pain - Acute care edition Australian Commission on Safety and Quality in Health Care, Standard 27/04/2022

Collection and usage attributes

Computation description:	The numerator and denominator include patients admitted to hospital and non-admitted patients treated in the emergency department. CNS depressant medicines include benzodiazepines and other sedative hypnotics, barbiturates and gabapentinoids. Presented as a percentage.
Computation:	$(\text{Numerator} \div \text{Denominator}) \times 100$
Numerator:	Number of patients in the denominator who were newly prescribed central nervous system depressant medicines while in hospital.
Denominator:	Number of patients who were newly prescribed opioid analgesics while in hospital.
Comments:	This indicator is based on existing indicators in use in the United States. For example, the following indicator by the American Hospital Association (2020) 'Percentage of patients with opioids and benzodiazepines coprescribed'.

Representational attributes

Representation class:	Percentage
Data type:	Real
Unit of measure:	Service event
Format:	N[NN]

Source and reference attributes

Submitting organisation:	Australian Commission on Safety and Quality in Health Care
---------------------------------	--

Reference documents:

American Hospital Association. Stem the Tide: Opioid Stewardship Measurement Implementation Guide. Washington, DC: AMA; 2020. Available from: www.aha.org/opioids

Australian Commission on Safety and Quality in Health Care. Opioid Analgesic Stewardship in Acute Pain Clinical Care Standard – Acute care edition. Sydney: ACSQHC; 2022.